文献速递浆细胞疾病

造血评分可预测新诊断多发性骨髓瘤患者的结局

Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients.
PubMed 文献 · Am J Hematol · 2019-10-29

该回顾性研究纳入2004年至2018年在Mayo Clinic治疗的1540例新诊断多发性骨髓瘤患者,基于血红蛋白<10 g/dL、血小板<150×10^9/L和平均红细胞体积>96 fL三项指标各计1分构建造血评分。评分将患者分为4组,各组无进展生存期和总生存期随评分升高而显著缩短,多变量分析显示造血评分(0-2 vs 3)是总生存期的独立预测因素。

要点

  • 造血评分由Hgb<10 g/dL、Plt<150×10^9/L、MCV>96 fL三项各1分组成。

核心结论

  • 造血评分可预测新诊断多发性骨髓瘤患者的总生存期和无进展生存期。

研究设计与样本

  • 回顾性研究,纳入2004年1月至2018年4月在Mayo Clinic治疗的1540例新诊断多发性骨髓瘤患者。

主要发现

  • 评分0、1、2、3分患者分别占46%(707例)、33%(513例)、17%(260例)、4%(60例)。

关键数值与推荐

  • 评分指标:血红蛋白<10 g/dL、血小板<150×10^9/L、平均红细胞体积>96 fL,每项1分。

临床怎么用

  • 该评分基于常规血液学指标,可在诊断时用于多发性骨髓瘤患者的风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Risk stratification of multiple myeloma (MM) at diagnosis is critical. We examined the ability of hematopoietic indices including mean corpuscular volume (MCV), hemoglobin (Hgb), and platelet (Plt) to predict outcomes. This was a retrospective study of patients treated at Mayo Clinic between January 2004 and April 2018. We incorporated three variables (Hgb < 10 g/dL, Plt < 150 × 109 /L, and MCV > 96 fL), assigning a score of 1 to each. We identified 1540 newly diagnosed MM patients, of whom 707 (46%) had a score of 0, 513 (33%) had a score of 1, 260 (17%) had a score of 2, and 60 (4%) had a score of 3. The score risk stratified patients into four groups with differing survivals. The median PFS was 32.3 months for score 0, 24.8 months for score 1, 21.7 months for score 2, and 18.3 months for score 3, for P < .001. The median OS was 80.7 months for score 0, 59.9 months for score 1, 51.7 months for score 2, and 31.3 months for score 3, P < .0001. Predictors of OS on the multivariable analysis were age ≥ 65 (HR, 1.93; P < .0001), R-ISS stage (1-2 vs 3) (HR, 0.48; P < .0001), and hematopoietic score (0-2 vs 3) (HR, 0.51; P = .006). A hematopoietic score can predict survival in newly diagnosed myeloma patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Al Saleh AS, Sidiqi MH, Dispenzieri A, et al. Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. Am J Hematol. 2019. PMID: 31612526. doi:10.1002/ajh.25657

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。